Bicycle Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

bicycletherapeutics.com

Stage

IPO | IPO

Total Raised

$90M

Date of IPO

5/23/2019

About Bicycle Therapeutics

Bicycle Therapeutics (Nasdaq: BCYC) is a clinical-stage biopharmaceutical company developing a class of medicines referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained to form two loops that stabilize their structural geometry. This constraint is designed to confer high affinity and selectivity, and the relatively large surface area presented by the molecule allows targets to be drugged that have historically been intractable to non-biological approaches.

Bicycle Therapeutics Headquarter Location

B900 Babraham Research Campus

Cambridge, England, CB22 3AT,

United Kingdom

+44 (0)1223 497 415

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Bicycle Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Bicycle Therapeutics is included in 3 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Bicycle Therapeutics Patents

Bicycle Therapeutics has filed 17 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • EC 3.4.24
  • Matrix metalloproteinases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/8/2012

10/13/2020

Transcription factors, EC 3.4.21, Protein domains, Peptides, Clusters of differentiation

Grant

Application Date

10/8/2012

Grant Date

10/13/2020

Title

Related Topics

Transcription factors, EC 3.4.21, Protein domains, Peptides, Clusters of differentiation

Status

Grant

Latest Bicycle Therapeutics News

Bicycle Therapeutics plans jobs surge both sides of the Atlantic

May 20, 2022

Bicycle Therapeutics revealed a double power play on both sides of the Atlantic after showcasing its new Cambridge headquarters at Granta Park. Chief executive Kevin Lee and chair Pierre Legault laid out bold expansion plans for operations in the UK and US as the life science doyen embarks on a golden era and looks to swell headcount by more than 30 per cent in the next seven months. Bicycle is already close to 180 employees – around 125 of them in the UK and 55 in America. By the end of the year it expects to be closer to 250. And as Legault told dignitaries at the opening ceremony, the company has ambitions to move into a new US site as well. Its current US base is in Lexington Massachusetts, northwest of Boston, and is where the first shot of the American Revolutionary War was fired. Legault revealed that a new US flagship would seek to optimise the life science gravitas of the Greater Boston cluster, just as the business was leveraging Cambridge brainpower in the UK. US real estate giant BioMed Realty lured Bicycle from Babraham into the new Granta Park building and persuaded Jeff Bezos’ anti-ageing technology trailblazer – Altos Labs – to take even more space right next door in the renovated Portway Building. Altos, which starts life with $3 billion in its coffers, will also soon be hitting its straps although it is not yet ready to reveal precise hire numbers. With a UK debate raging about the respective benefits of home and office working, Bicycle has fitted out its new HQ accordingly, creating a home from home for its people. A state-of-the art games room and edge-of-tech reading, easy listening and other breakout areas are bonuses to the airy and expertly fitted out labs, offices and refreshment facilities. For the uninitiated, the company is developing a novel class of small, chemically synthesised medicines called Bicycles, initially targeting cancers. Some patients on the earliest trials are already said to be in remission. But the vision is much broader. Through collaborations with AstraZeneca, Oxurion, Innovate UK, the Dementia Discovery Fund and Ionis, Bicycle works with companies that have deep therapeutic expertise outside of oncology to enable the business to more efficiently develop novel medicines for patients in other disease areas. Co-founder and Nobel Prizewinner Sir Greg Winter (pictured above), who gave the keynote address at the opening ceremony, was typically honest in his assessment of the toil in the labs; the highs along the highway and the bumps in the road before Bicycle’s Eureka moment. Co-founder Christian Heinis told me later that the end result was worth the figurative blood, sweat and tears. Serial Cambridge life science entrepreneur Dr Andy Richards, who chairs some of our finest biotechs, is not someone who is easily impressed – but he heaped praise on the founders and the business they helped fashion. Dr Richards told me: “Bicycle Therapeutics is a totemically important biotech company to both the Cambridge ecosystem and to UK plc – and one that has made that successful transition to being a NASDAQ-quoted public company whilst still retaining its intellectual and corporate heart here in Cambridge. “Building on the visionary creative thinking of Sir Greg Winter and Christian Heinis it has established a world-leading platform that defines a new therapeutic modality – neither small molecule nor antibody – pulling on the advantages of both and with wide potential applicability across medicine and in almost all therapeutic areas. “The productivity of the discovery engine is a real strength but the challenge, as with all 'platform to product' ventures, comes in choosing the right targets and the right product profiles and then prosecuting the right products through to patients in the most suitable clinical trials – and all under the gaze of public market scrutiny where access to capital becomes a key success factor to be able to pursue a broad pipeline. “Biology is complicated and the unexpected often happens in clinical studies, but with such a radical new modality the 'unknown unknowns' are always present, so maintaining the balance of pipeline and continually learning gives the best chance of success. “Navigating through these challenges necessitates, bold decisions, resolute leadership and a great team – qualities that Kevin Lee and his executive continue to demonstrate. The promise is immense both to medicine and patients, and for our economy this is 'the one' whose continuing independence really matters.“ • Images courtesy of Bicycle Therapeutics Related Articles

Bicycle Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Bicycle Therapeutics Rank

  • Where is Bicycle Therapeutics's headquarters?

    Bicycle Therapeutics's headquarters is located at B900 Babraham Research Campus, Cambridge.

  • What is Bicycle Therapeutics's latest funding round?

    Bicycle Therapeutics's latest funding round is IPO.

  • How much did Bicycle Therapeutics raise?

    Bicycle Therapeutics raised a total of $90M.

  • Who are Bicycle Therapeutics's competitors?

    Competitors of Bicycle Therapeutics include Tavotek Biotherapeutics, Perseus Proteomics, OcuNexus Therapeutics, CoImmune, Acorda Therapeutics and 11 more.

You May Also Like

E
Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

L
Lead Pharma

Lead Pharma is a spinoff from the Hubrecht Institute and the University Medical Center Utrecht, developing innovative small-molecule therapies for patients with autoimmune disease or cancer.

I
Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.

F
FirstString Research

FirstString is a biopharmaceutical company dedicated to discovering therapies for inflammation-based medical conditions.

G
GRAPP

Grand River Aseptic Pharmaceutical Packaging is a pharmaceutical contract manufacturing organization (CMO) supporting the rapid development of new biomedicines to the clinical stage in the State of Michigan. Grand River APP is the result of an alliance between Van Andel Institute (www.vai.org) and Grand Valley State University, and is operating as a non-profit, state- and federally funded corporation. Grand River APP's first aims to assure that therapeutics are properly distributed into dosage forms for all-important Phase I and Phase II human clinical trials. This process, Fill/Finish and Lyophilization, will be offered broadly to academic, nonprofit, and for-profit organizations in Michigan and across North America for liquid-based drug candidates that require vialing in an FDA-regulated aseptic clean room environment. Typical products envisioned for Grand River APP services include small molecule drugs, peptides, monoclonal antibodies, therapeutic proteins and nano-medicines. As a consequence, however, Grand River APP cannot process cytotoxic/genotoxic or virally-based candidates (e.g. viral vaccines).

C
Carticure

CartiCure is a MedTech company for tissue engineering; developing innovating technology for cartilage repair. CartiCure's technological platform generates original hyaline cartilage-producing cells to be transplanted into damaged joints; efficiently replenishing small and large lesions in the articular cartilage.nCarticure was established in 2005 and is currently based on the premises of the NGT High-Tech Incubator in Nazareth, Israel; all scientific work as well as on-going animal trials are being conducted at the Faculty of Medicine at Technion-Israel Institute of Technology in Haifa, Israel.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.